FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings

By /

Corcept’s relacorilant was rejected for hypercortisolism late last year—a decision which CEO Joseph Belanoff expressed surprise with at the time.

Scroll to Top